{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:53:48Z","timestamp":1779904428554,"version":"3.53.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2022.02.018","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T20:12:27Z","timestamp":1646424747000},"page":"141-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["In vitro activity of ceftazidime\/avibactam against Gram-negative strains in Colombia 2014\u20132018"],"prefix":"10.1016","volume":"29","author":[{"given":"Elkin V.","family":"Lemos-Luengas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixta","family":"Renter\u00eda-Valoyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"C\u00e1rdenas-Isaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Ramos-Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.02.018_bib0001","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10388","article-title":"Antibiotic resistance is ancient","volume":"477","author":"D\u2019Costa","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jgar.2022.02.018_bib0002","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1590\/S1020-49892001001000014","article-title":"Estrategia mundial de la OMS para contener la resistencia a los antimicrobianos","volume":"10","author":"Organizaci\u00f3n Mundial de la","year":"2001","journal-title":"Rev Panam Salud P\u00fablica"},{"issue":"3","key":"10.1016\/j.jgar.2022.02.018_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106045","article-title":"In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015\u20132017","volume":"56","author":"Stone","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jgar.2022.02.018_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.05.007","article-title":"Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012\u20132016","volume":"96","author":"Stone","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.jgar.2022.02.018_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199531","article-title":"Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance","volume":"13","author":"Garcia-Vidal","year":"2018","journal-title":"PLOS One"},{"key":"10.1016\/j.jgar.2022.02.018_bib0006","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1186\/s12879-021-06243-z","article-title":"Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance","volume":"21","author":"Amanati","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.jgar.2022.02.018_bib0007","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1099\/jmm.0.001273","article-title":"High mortality by nosocomial infections caused by carbapenem-resistant P. aeruginosa in a referral hospital in Brazil: facing the perfect storm","volume":"69","author":"Urzedo","year":"2020","journal-title":"J Med Microbiol"},{"issue":"5","key":"10.1016\/j.jgar.2022.02.018_bib0008","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jinf.2018.02.007","article-title":"Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: systematic review and meta-analysis","volume":"76","author":"Ramos-Casta\u00f1eda","year":"2018","journal-title":"Journal of Infection"},{"key":"10.1016\/j.jgar.2022.02.018_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4067\/S0716-10182017000100001","article-title":"Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia 2011\u20132015","volume":"34","author":"Osorio","year":"2017","journal-title":"Revista chilena de infectolog\u00eda"},{"issue":"6","key":"10.1016\/j.jgar.2022.02.018_bib0010","article-title":"In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017\u20132019","volume":"25","author":"Karlowsky","year":"2021","journal-title":"Braz J Infecti Dis"},{"issue":"10","key":"10.1016\/j.jgar.2022.02.018_bib0011","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.02.018_bib0012","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2147\/IDR.S209264","article-title":"Optimal management of complicated infections in the pediatric patient: the role and utility of ceftazidime\/avibactam","volume":"13","author":"Bassetti","year":"2020","journal-title":"Infect Drug Resist"},{"issue":"7","key":"10.1016\/j.jgar.2022.02.018_bib0013","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jgar.2022.02.018_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106439","article-title":"Activity of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales (CRE) isolates from US hospitals","volume":"58","author":"Castanheira","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.jgar.2022.02.018_bib0015","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA global surveillance program: ceftolozane\/tazobactam and ceftazidime\/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"Gill","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.018_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jgar.2021.08.010","article-title":"In vitro activity of ceftazidime\/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018","volume":"27","author":"Kiratisin","year":"2021","journal-title":"J Global Antimicrob Resist"},{"issue":"12","key":"10.1016\/j.jgar.2022.02.018_bib0017","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/jac\/dkab306","article-title":"Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime\/avibactam, meropenem\/vaborbactam and comparators against these isolates","volume":"76","author":"Castanheira","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jgar.2022.02.018_bib0018","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/antibiotics9020062","article-title":"In vitro susceptibility to ceftazidime\/avibactam and comparators in clinical isolates of enterobacterales from five Latin American countries","volume":"9","author":"Appel","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2022.02.018_bib0019","unstructured":"Resoluci\u00f3n No. 2019052727 de Noviembre 22 de 2019 [Internet]. Ministerio de Salud y Protecci\u00f3n Social, Instituto Nacional de Vigilancia de Medicamentos y Alimentos \u2013 INVIMA. 2019 [Access on: 14 noviembre 2021]. Available on: https:\/\/www.invima.gov.co\/documents\/20143\/1587207\/INVIMA+2019M+19450-2019052727.pdf."},{"key":"10.1016\/j.jgar.2022.02.018_bib0020","unstructured":"Dowzicky MJ. ATLAS: Fully\u2010searchable Global Antibiotic Resistance Database to Fight AMR 2019 [Internet]. 2019 [Access on: 2021 Nov 8]. Available at: https:\/\/www.amr-insights.eu\/wp-content\/uploads\/2019\/06\/ATLAS_Fully-searchable-global-AMR-database-to-fight-AMR_Michael-Dowzicky_Pfizer_ADTCA2019.pdf."},{"key":"10.1016\/j.jgar.2022.02.018_bib0021","series-title":"Performance Standards for Antimicrobial Susceptibility Testing. 29th ed","year":"2019"},{"issue":"11","key":"10.1016\/j.jgar.2022.02.018_bib0022","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jgar.2022.02.018_bib0023","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/antibiotics9070388","article-title":"Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis","volume":"9","author":"Fiore","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"10.1016\/j.jgar.2022.02.018_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant Gram-negative bacteria other than carbapenem-resistant Enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"10.1016\/j.jgar.2022.02.018_bib0025","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u22653 months to <18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.jgar.2022.02.018_bib0026","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime\u2013avibactam in the treatment of children \u22653 months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dise J"},{"issue":"6","key":"10.1016\/j.jgar.2022.02.018_bib0027","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jgar.2022.02.018_bib0028","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jgar.2022.02.018_bib0029","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ijantimicag.2019.06.008","article-title":"Cost-effectiveness analysis of ceftazidime\/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections","volume":"54","author":"Kongnakorn","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.jgar.2022.02.018_bib0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14737167.2021.1964960","article-title":"Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to carbapenem-resistant Klebsiella pneumoniae in Colombia","volume":"22","author":"Var\u00f3n-Vega","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jgar.2022.02.018_bib0031","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jgar.2021.04.001","article-title":"Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies","volume":"25","author":"Di Bella","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2022.02.018_bib0032","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jgar.2021.04.010","article-title":"In vitro activity of ceftazidime\/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany","volume":"25","author":"Kresken","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"10.1016\/j.jgar.2022.02.018_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01814-18","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.02.018_bib0034","series-title":"M100 Performance Standards for Antimicrobial Susceptibility Testing","year":"2020"},{"issue":"10","key":"10.1016\/j.jgar.2022.02.018_bib0035","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/jac\/dky266","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012\u201315","volume":"73","author":"Kazmierczak","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jgar.2022.02.018_bib0036","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014)","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jgar.2022.02.018_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02463-18","article-title":"Successful treatment of a bacteremia due to NDM-1-producing Morganella morganii with Aztreonam and Ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy","volume":"63","author":"Hobson","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522000534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522000534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:02:54Z","timestamp":1761991374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522000534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":37,"alternative-id":["S2213716522000534"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.02.018","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftazidime\/avibactam against Gram-negative strains in Colombia 2014\u20132018","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}